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Abstract
Clinical Relevance: Late complications can occur with use of current antimetabolites to prevent scarring following
glaucoma filtration surgery (GFS). Safer, more targeted, anti-fibrosis agents are sought.
Objectives: The protein saratin has been shown to exhibit anti-fibrotic and anti-thrombotic properties in response to injury,
but had not been used for glaucoma surgery. The goal of this study was to compare the efficacy of saratin with that of the
widely accepted mitomycin-C (MMC) in prolonging bleb survival following GFS in the rabbit model. Two saratin delivery
routes were compared; a single intraoperative topical application versus a combination of intraoperative topical application
with two additional postoperative injections.
Methods: Twenty-four New Zealand White rabbits underwent GFS and received either intraoperative topical saratin,
intraoperative topical saratin plus two injections on post-operative days 4 and 8, balanced saline solution (BSS), or MMC. The
bleb tissues and their elevation durations were compared based on clinical and histological findings.
Results: Rabbits receiving topical+injections of saratin had a mean bleb survival of 33.668.5 days, significantly higher than
the negative BSS controls, which averaged 17.466.0 days (p=0.018). No improvement over BSS was seen for rabbits
receiving topical saratin only (15.564.8 days, p=0.749). Rabbits receiving saratin did not develop bleb avascularity and
thinning associated with MMC treatment and there were no apparent clinical signs of toxicity.
Conclusions: Treatment with a single intraoperative topical application plus two additional postoperative injections
significantly prolonged bleb elevation comparable to MMC, but without toxicity; however, topical application alone was
ineffective.
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Introduction
Glaucoma filtration surgery (GFS) remains the gold standard for
the management of intraocular pressure (IOP) when medication
and laser surgery have proven insufficient [1,2]. However, scar
tissue due increased fibroblast proliferation and activation can
form between the conjunctiva/Tenon’s capsule and the sclera at
the surgical site often months or years after surgery, obstructing
aqueous flow and causing the filter to fail [3,4].
The antimetabolites mitomycin-C (MMC) and 5-fluorouracil (5-
FU) are used in current clinical practice to help limit post-
operative ocular scar tissue formation. While these agents have
been shown to improve the IOP outcome of GFS, they do so in a
non-selective manner [5]. As a result, antimetabolite treatment is
associated with a significant side-effect profile, including hypotony,
blebitis, endophthalmitis, bleb leakage, and vision loss in a few
[2,3,5–8]. Recent studies into alternative methods of preventing
tissue fibrosis have focused on the inhibition of Tenon’s capsule
fibroblasts through the regulation of various growth factors [9–11].
Some success in reducing scar formation after GFS by inhibiting
vascular endothelial growth factor (VEGF) and transforming
growth factor-b (TGF-b) has been reported in recent literature
[5,12,13].
The focus of this investigation is to examine the ability of saratin
to limit ocular scarring following GFS. Saratin is a 12 kD protein
which was originally isolated from the saliva of the leech Hirudo
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a2b1-collagen and von Willebrand factor-collagen binding,
preventing platelet aggregation in response to injury [14–17]. To
date, saratin has been shown to be effective in preventing platelet
adhesion and intimal hyperplasia in both animal and human
models [18,19]. Recent studies in human models have shown that
the protein has potent antithrombotic properties, making it useful
in the treatment of atherosclerotic lesions [20].
Evidence also suggests that saratin can potentially reduce
inflammation by limiting the immune response at the site of tissue
injury. Primarily, it is thought that the protein interferes with the
binding of inflammatory cells to extracellular matrix proteins, a
necessary step for cell migration toward wound sites [21]. In vitro
Boyden chamber assays indicated that saratin inhibits the
chemotaxis of human monocytes and T-lymphocytes toward the
chemokines MCP-1 and MIP-1a, respectively [22]. Secondarily,
by interfering with platelet aggregation at the wound site, saratin
limits the release of platelet-derived growth factor (PDGF), TGF-
b, insulin-like growth factor (IGF), and epidermal growth factor
(EGF) [23]. These growth factors have been shown to contribute
toward accelerated ocular wound healing by stimulating prolifer-
ation, migration, and collagen production in Tenon’s capsule
fibroblasts [10,11,24,25].
The rabbit model is well-established as a standard animal model
for the investigation of wound healing and scarring following GFS
[25–28]. Our experiment investigates the ability of saratin to
reduce fibrotic activity at the site of GFS. To our knowledge, this is
the first reported ocular use of the saratin protein. The primary
goals of this study were to evaluate potential methods of delivering
saratin, as well as to compare the overall efficacy of saratin versus a
BSS negative control and a MMC positive control. An additional
aim for this project was to identify potential side effects of
treatment using saratin.
Methods and Materials
Twenty four New Zealand White rabbits weighting between
2 kg and 4 kg were used for this study. All animal experiments
performed adhered to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and were approved
by the University of Florida’s Institutional Animal Care and Use
Committee.
Study Design
The rabbits were randomized to one of 4 different treatment
groups of six rabbits each. All 24 rabbits underwent glaucoma
filtering operation in their left eyes with one surgeon (MBS)
performing the procedures; the right eyes were not operated on
and served as controls.
Rabbits in the first experimental group received a single topical
application of saratin at 5 mg/ml applied intraoperatively using a
standardized 5 mm65 mm partial-thickness Weck cell (Alcon
Surgical, Fort Worth, TX), immediately following the fashioning
of a fornix-based conjunctival flap.
Rabbits in the second experimental group also received a
topical application with the partial-thickness Weck cell sponge at
the time of surgery. In addition, two 0.1 ml subconjunctival
injections of saratin at 5 mg/ml were administered on post-
operative days (POD) 4 and 8. The protein saratin used in both
experimental groups one and two was supplied by BioVascular,
Inc., is now made by recombinant expression in yeast (Hansenula
polymorpha) and purified to greater than 95% purity.
To provide a more accurate comparison to the experimental
groups, all rabbits in the negative control group received an
intraoperative topical application of BSS. Three (half) of the
rabbits in this group also received 0.1 ml subconjunctival
injections of BSS on POD 4 and 8 to match group 2 rabbits
and three did not in order to mimic group 1 rabbits and MMC
positive controls. All postoperative subconjunctival injections were
given following bleb examination by the masked observer, and the
injection material remained unknown to both the observer and the
clinician giving the injection.
Finally, rabbits in the positive control group received a topical
application of 0.4 mg/ml mitomycin-C at the time of surgery and
were not given any post-operative injections.
Glaucoma Filtering Operation
The rabbits were anesthetized with an intramuscular injection
of a combination of 50 mg/kg ketamine (‘‘Ketaject’’, Phoenix,
Mo) and 10 mg/kg xylazine (‘‘Xyla-ject’’, Phoenix, Mo). A topical
anesthetic, 0.1% proparacaine eye drop (Bausch & Lomb, Tampa,
FL), was also administered. The surgical technique for the
glaucoma filtration operations was similar to the procedures
described in previous publications [25]. In brief, an eyelid
speculum retracted the eyelids. A partial-thickness, corneal
traction suture made in the superior cornea rotated the eye
inferiorly. In the superior lateral quadrant of the eye at the limbus,
a measured standard sized 5 mm fornix-based conjunctival flap
was created. Blunt dissection helped undermine the conjunctiva
and Tenon’s capsule. At this point, a 5 mm65 mm partial-
thickness Weck cell (Alcon Surgical, Fort Worth, TX) soaked in
5 mg/ml saratin, 0.4 mg/ml mitomycin-C, or BSS depending on
the treatment group was placed locally between the conjunctiva/
Tenon’s capsule and the sclera. After 5 minutes, the sponge was
removed and the area was washed with 30 ml of saline. Next, a
clear corneal paracentesis tract was fashioned in the superonasal
quadrant using a # 75 Beaver
TM blade (Becton Dickinson & Co.,
Franklin Lakes, NJ). A viscoelastic material (HealonH 10mg/ml,
Pharmacia & Upjohn) was injected to maintain the anterior
chamber.
A 25-gauge needle was then used to create a beveled, full-
thickness tract through the sclera into the anterior chamber about
1 mm posterior to the limbus. This was followed by insertion of a
22-gauge, IV cannula (InsyteH Becton Dickinson Vascular Access,
Sandy, UT) along this tract into the anterior chamber. The
cannula needle was pulled out, and the cannula was positioned
beyond the pupillary margin to prevent the tube from being
occluded by iris. The cannula was trimmed at its scleral end so it
would not protrude more than approximately 1 mm from the
point of insertion. A 10–0 nylon suture (Ethicon Inc., Somerville,
NJ) was used to anchor the tube to the sclera.
A running suture of 8–0 absorbable suture material (VicrylH,
Ethicon Inc., Somerville, NJ) was used to close the conjunctiva/
Tenon’s capsule at the limbus in a watertight fashion. At the end of
the procedure, saline was injected into the anterior chamber via
the paracentesis tract to elevate the bleb and a Seidel test
performed to ensure that there was no bleb leak. An ointment of
neomycin and dexamethasone was applied topically immediately
following the surgery.
Post-Operative Injections and Clinical Evaluations
Following the operation, the eyes were examined three times
per week by an examiner masked to the treatment group. The
examiner looked for the presence of bleb elevation as well as for
any complications that may have resulted from the surgeries or
various treatments, including conjunctival injection, edema,
anterior chamber shallowing, tube mal-positioning, hyphema or
sub-conjunctival hemorrhage, bleb leaks, and corneal or lens
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deemed the bleb to be flat in two consecutive examinations. The
first of the two dates was recorded as the endpoint. When
applicable, rabbits in the saratin and BSS treatment groups were
also given injections of 0.1 ml saratin or 0.1 ml BSS respectively
on POD 4 and 8.
The rabbits were anesthetized with isoflurane during their post-
operative examinations, and a topical 0.1% proparacaine
anesthetic eye drop was administered for those that required a
post-op injection. A speculum was used to retract the eyelids. Non-
toothed Bishop-Harmon forceps were used to tent the conjunctiva,
and the 0.1 ml injections were given near the bleb using a 30-
gauge needle on a 1 ml syringe on POD 4 and 8.
Histology
Eyes were obtained from one rabbit in each of the four groups
on post-operative day (POD) 12 so bleb tissues could be examined
at a uniform time. Eyes were obtained from all other rabbits after
the bleb was observed to be flat in two consecutive clinical
evaluations.
The tissues were fixed for 24 hours in a 10% neutral buffered
formalin solution. The globes were placed in tissue cassettes,
and then processed through graded ethanol and xylene using a
Sakura Tissue-Tek VIP 5 tissue processor (Torrance, CA). The
tissues were infiltrated with paraffin (Richard-Allan Scientific,
Kalamazoo, MI) and embedded on a Tissue Tek III embedding
center. Sagittal serial sections of the globes were taken. Once
deparaffinized, the sections were stained using either standard
Harris hematoxylin and eosin or Masson’s trichrome. The slides
were examined under light microscopy by an observer masked
to the treatment groups and representative sections were
photographed using a Canon EOS T1i digital camera attached
to an Olympus Vanox microscope. The slides were qualitatively
graded based upon collagen and fibroblast densities and
vascularity in the tissues around the end of the cannula, plus
preservation of the conjunctival tissue morphology including
goblet cell numbers.
Statistical Analysis
Analysis of Variance (ANOVA) testing was used to determine
any significant difference in bleb survival duration among the
treatment groups. Tukey’s Honestly Significantly Different (HSD)




Rabbits receiving a single 5 minute topical application of
saratin had an average time to bleb failure of 15.5
+/– 4.8 days.
Rabbits receiving two additional injections of saratin on POD 4
and 8 had an average time of 33.6
+/– 8.5 days. The average
time to bleb failure for rabbits receiving BSS injections/topical
application was 17.4
+/– 6.0 days. Rabbits receiving MMC
treatments had bleb elevation durations averaging 41.6+/–
13.0 days. The rabbits from each treatment group sacrificed on
POD 12 for histologic comparison were omitted from these data
calculations. These results are represented in a Kaplan-Meier
survival plot (Fig. 1) and summarized using a box-and-whisker
plot (Fig. 2).
Analysis of variance (ANOVA) testing revealed a significant
difference among the treatment groups (p=0.001) at a 95%
confidence interval. Post-hoc testing with Tukey’s Honestly
Significant Different (HSD) showed that the MMC rabbit group
had a significantly longer bleb survival duration than the BSS
group at a 95% confidence interval. In addition, there was a
significant difference in bleb survival duration between the
topical+injection saratin group and the BSS group at a 90%
confidence interval. No significant improvements over BSS were
found for the topical-only saratin group at a 90 or 95% confidence
interval. Finally, there was no statistically significant difference
between the MMC group and the topical+injection saratin
treatment group at a 90% or 95% confidence interval.
Clinical Evaluation
Blebs treated with MMC developed avascularity that was not
observed in either saratin or BSS groups. There were no clinical
signs of obvious toxicity to saratin treatments.
Figure 1. Kaplan-Meier bleb survival plot of eyes in each
treatment group. For each rabbit, bleb failure was declared after the
bleb appeared flat in two consecutive masked clinical examinations.
The first of the two dates was recorded as the endpoint.
doi:10.1371/journal.pone.0035627.g001
Figure 2. Box-and-whisker plot of bleb survival for each
treatment group. First and third quartiles are delineated by boxes.
Whiskers represent maxima and minima.
doi:10.1371/journal.pone.0035627.g002
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Histological examination focused on samples taken on post-
operative day 12 to provide a common time-point of comparison
(Fig. 3 & 4). Among all treatment groups, a zone of fibroblast
proliferation with associated intracellular collagen was observed
bordering the site of the implant. A variable infiltration of plasma
cells and polymorphonuclear leukocytes (PMNLs) was evident
within this area. The rabbits that received saratin by either topical
application or injections had a mild collagen density and a
moderate fibroblast proliferation. The group that received BSS
showed a mild to moderate fibroblast density and a collagen
density similar to the animals in the saratin group. The MMC
group showed slightly less fibrosis, with minimal to mild collagen
and fibroblast density highlighted by a large region of acellular
fibrosis and necrosis (Fig. 4, right). The conjunctiva of rabbits
treated with saratin did not exhibit avascularity, tissue thinning,
and change in epithelial morphology from pseudostratified
columnar to stratified squamous with a loss of mucin-producing
(goblet) cells typical of MMC treatment (Fig. 5).
Discussion
In this study we examined the antifibrotic effects of saratin, a
protein which has been previously investigated as an antithrom-
botic agent. Because the application of saratin in GFS was a novel
use for the protein, we tested two methods of delivering the drug.
The first experimental group received only an intraoperative
topical application similar to the method in which MMC is
currently administered. A second experimental group received a
combined treatment of topical saratin with additional subcon-
junctival injections on POD 4 and 8. Because the amount of
saratin retained in ocular tissues is unknown, the injections in the
latter treatment modality ensured high amounts of the protein
over an extended duration.
Statistical analysis showed that intraoperative topical saratin
alone did not improve bleb survival compared to BSS negative
controls. The Kaplan-Meier survival plot (Fig. 1) and box-and-
whisker plot (Fig. 2) show that rabbits in the topical saratin group
performed similarly to those in the BSS group. However, the
group which received postoperative injections of saratin in
addition to topical application had a significant improvement
over BSS negative controls and was comparable to the MMC
positive control group. While the mean for the topical+injection
saratin group was slightly less than that of the MMC group
(33.6
+/– 8.5 days vs. 41.6+/– 13.0 days), the difference was not
statistically significant.
When applied topically for a brief period of 1–5 minutes, MMC
has an immediate effect on local tissues by alkylating and
crosslinking DNA, as well as inhibiting DNA synthesis, transcrip-
tion, and translation [29]. Topical saratin, when administered in a
similar manner for 5 minutes did not improve bleb survival
beyond that of the BSS control. When two post-operative
subconjunctival injections were given in addition, there was a
significant improvement over BSS control and the bleb survival
was not significantly different from the MMC positive control. The
ineffectiveness of topical saratin when administered at surgery
using a partial-thickness Weck cell sponge suggests three
possibilities; either a lack of local uptake of the saratin from the
sponge, or that contact with the tissues was not long enough to
produce an effect, or that peroperative application is not the most
effective time to deliver saratin compared to early post-operative
treatment. The optimal delivery route, number of applications,
and the half-life of saratin in the ocular tissues warrant further
study.
Figure 3. Representative sections of the implant site taken on POD 12, H&E 20x; (A) Topical saratin; (B) Topical+2 injections of
saratin; (C) Balanced saline solution; (D) Mitomycin-C.
doi:10.1371/journal.pone.0035627.g003
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bleb avascularity and tissue thinning, including alteration in
epithelial structure, commonly associated with MMC treatment.
While the topical+injection group did not outperform MMC, the
effects of MMC have been extensively studied and the dosage
optimized [2,3,5–8,29]. Further studies on saratin may be
necessary to improve the dosing regimen and to provide additional
information regarding potential side-effects.
Figure 4. Representative sections of the implant site taken on POD 12, Masson’s Trichrome 20x; Left: Topical+2 injections of
saratin; asterisk, mild collagen density and moderate fibroblast proliferation Middle: Balanced saline solution; Right: Mitomycin-C;
asterisk, acellular fibrosis and necrosis.
doi:10.1371/journal.pone.0035627.g004
Figure 5. Representative sections of the bleb conjunctiva taken on POD 12, H&E 250x; (A) Topical saratin; (B) Topical+2 injections
of saratin; (C) Balanced saline solution; (D) Mitomycin-C.
doi:10.1371/journal.pone.0035627.g005
Use of Saratin to Prevent Scarring Post GFS
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35627Acknowledgments
The authors would like to thank BioVasc Incorporated for supplying the
protein saratin used in the study as well as funding for the research. We
also extend thanks to the Research to Prevent Blindness for their generous
grant.
Author Contributions
Conceived and designed the experiments: ZLL JM MBS. Performed the
experiments: ZLL JM MAL CAM ARB MBS. Analyzed the data: JM
MAL ZLL. Contributed reagents/materials/analysis tools: GSS DAS.
Wrote the paper: MAL JM ZLL MBS.
References
1. Burr J, Azuara-Blanco A, Avenell A (2005) Medical versus surgical interventions
for open angle glaucoma. Cochrane Database Syst Rev 18: CD004399.
2. DeBry PW, Perkins TW, Heatley G, et al. (2002) Incidence of late-onset bleb-
related complications following trabeculectomy with mitomycin. Arch Ophthal-
mol 120: 297–300.
3. Muckley ED, Lehrer RA (2004) Late-onset blebitis/endophthalmitis: incidence
and outcomes with mitomycin C. Optom Vis Sci 81: 499–504.
4. Francis BA, Du LT, Najafi K, Murthy R, Kurumety U, et al. (2005)
Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol 123:
166–70.
5. Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, et al. (2009)
Inhibition of vascular endothelial growth factor reduces scar formation after
glaucoma filtration surgery. Invest Ophthal Vis Sci 50: 5217–5225.
6. Bindlish R, Condon GP, Schlosser JD, D’Antonio J, Lauer KB, et al. (2002)
Efficacy and safety of mitomycin-C in primary trabeculectomy: five year follow-
up. Ophthalmology 109: 1336–1341.
7. Anand N, Arora S, Clowes M (2006) Mitomycin C augmented glaucoma
surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and
leaks. Br J Ophthalmol. 90: 175–180.
8. Beckers HJ, Kinders KC, Webers CA (2003) Five-year results of trabeculectomy
with mitomycin C. Graefes Arch Clin Exp Opthalmol 241: 106–10.
9. Denk PO, Hoppe J, Hoppe V, Knorr M (2003) Effect of growth factors on the
activation of human Tenon’s capsule fibroblasts. Curr Eye Res 27: 35–44.
10. Schultz G, Khaw PT, Oxford K, MaCauley S, Van Setten G, et al. (1994)
Growth factors and ocular wound healing. Eye 8: 184–187.
11. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, et al. (1994)
Activation and suppression of fibroblast function. Eye 8: 188–195.
12. Meyer-ter-Vehn T, Katzenberger B, Han H, Grehn F, Schlunck G (2008)
Lovastatin inhibits TGF-b–induced myofibroblast transdifferentiation in human
tenon fibroblasts. Invest Ophthal Vis Sci 49: 3955–3960.
13. Xiao YQ, Liu K, Shen JF, Xu G, Ye W (2009) SB-431542 inhibition of scar
formation after filtration surgery and its potential mechanism. Invest Ophthal
Vis Sci 50: 1698–1706.
14. Barnes CS, Krafft B, Frech M, Hofmann UR, Papendieck A (2001) Production
and characterization of saratin, an inhibitor of von Willebrand factor-dependent
platelet adhesion to collagen. Semin Thromb Hemost 24: 337–348.
15. Bonnefoy A, Romijn RA, Vandervoort PA, VAN Rompaey I, Vermylen J, et al.
(2006) Von Willebrand factor A1 domain can adequately substitute for A3
domain in recruitment of flowing platelets to collagen. J Thromb Taemost 4:
2151–61.
16. White TC, Berny MA, Robinson DK, Yin H, DeGrado WF, et al. (2007) The
leech product saratin is a potent inhibitor of platelet integrin alpha2beta1 and
von Willebrand factor binding to collagen. FEBS J 274: 1481–1491.
17. Gronwald W, Bomke J, Maurer T, Domogalla B, Huber F, et al. (2008)
Structure of the leech protein saratin and characterization of its binding to
collagen. J Mol Biol 381: 913–927.
18. Smith TP, Alshafie TA, Cruz CP, Fan CY, Brown AT, et al. (2003) Saratin, an
inhibitor of collagen-platelet interaction, decreases venous anastomotic intimal
hyperplasia in a canine dialysis access model. Vasc Endovascular Surg 37:
259–69.
19. Davis JA, Brown AT, Alshafie T, Poirier LA, Cruz CP, et al. (2004) Saratin (an
inhibitor of platelet-collagen interaction) decreases platelet aggregation and
homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a
dose-dependent manner. Am J Surg 188: 778–785.
2 0 .V i l a h u rG ,D u r a nX ,J u a n - B a b o tO ,C a s a n iL ,B a d i m o nL( 2 0 0 4 )
Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb
Haemost 95: 191–200.
21. Dugrillon A, Eichler H, Kern S, Kluter H (2002) Autologous concentrated
platelet-rich plasma (cPRP) for local application in bone regeneration. Int J Oral
Maxillofac Surg 31: 615–9.
22. Glidden PF (2010) Methods and compositions for blocking platelet and cell
adhesion, cell migration and inflammation. Patent No. US7691839B2 p.
23. Gehring S, Hoerauf H, Laqua H, Kirchner H, Kluter H (1999) Preparation of
autologous platelets for the ophthalmic treatment of macular holes. Transfusion
39: 144–148.
24. Knorr M, Volker M, Denk PO, Wunderlich K, Thiel HJ (1997) Proliferative
response of cultured human Tenon’s capsule fibroblasts to platelet-derived
growth factor isoforms. Graefe’s Arch Clin Exp Ophthalmol 235: 667–671.
25. Cordeiro MF, Constable PH, Alexander RA, Bhattacharya SS, Khaw PT (1997)
Effect of varying the mitomycin-C treatment area in glaucoma filtration surgery
in the rabbit. Invest Ophthalmol Vis Sci 38: 1639–1646.
26. Sherwood MB, Esson DW, Neelakantan A, Samuelson DA (2004) A new model
of glaucoma filtering surgery in the rat. J Glaucoma 13: 407–12.
27. Doyle JW, Sherwood MB, Khaw PT, McGrory S, Smith MF (1993)
Intraoperative 5-fluorouracil for filtration surgery in the rabbit. Invest
Ophthalmol Vis Sci 34: 3313–3319.
28. Connon CJ, Meek KM (2003) Organization of corneal collagen fibrils during the
healing of trephined wounds in rabbits. Wound Repair Regen 11: 71–78.
29. Khaw PT, Doyle JW, Sherwood MB, Smith MF, McGorray S (1993) Effects of
intraoperative 5-fluorouracil or mitomycin C on glaucoma filtration surgery in
the rabbit. Ophthalmology100: 367–72.
Use of Saratin to Prevent Scarring Post GFS
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35627